The Manufacturers Life Insurance Company Buys New Position in AnaptysBio, Inc. $ANAB

The Manufacturers Life Insurance Company bought a new position in shares of AnaptysBio, Inc. (NASDAQ:ANAB) during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 10,366 shares of the biotechnology company’s stock, valued at approximately $700,000.

Other institutional investors and hedge funds also recently bought and sold shares of the company. BlackRock Inc. bought a new position in shares of AnaptysBio during the 2nd quarter valued at about $124,473,000. Vanguard Group Inc. raised its holdings in shares of AnaptysBio by 4.5% in the 4th quarter. Vanguard Group Inc. now owns 1,544,037 shares of the biotechnology company’s stock worth $74,855,000 after purchasing an additional 67,048 shares in the last quarter. State Street Corp lifted its stake in AnaptysBio by 20.6% during the fourth quarter. State Street Corp now owns 1,053,474 shares of the biotechnology company’s stock valued at $51,072,000 after purchasing an additional 180,042 shares during the last quarter. Affinity Asset Advisors LLC boosted its holdings in AnaptysBio by 111.4% during the first quarter. Affinity Asset Advisors LLC now owns 940,000 shares of the biotechnology company’s stock worth $52,132,000 after buying an additional 495,308 shares in the last quarter. Finally, 683 Capital Management LLC boosted its holdings in AnaptysBio by 18.5% during the fourth quarter. 683 Capital Management LLC now owns 648,093 shares of the biotechnology company’s stock worth $31,420,000 after buying an additional 101,093 shares in the last quarter.

Analyst Ratings Changes

ANAB has been the subject of a number of recent research reports. Barclays increased their price objective on AnaptysBio from $63.00 to $75.00 and gave the company an “overweight” rating in a research report on Wednesday, May 13th. Wall Street Zen cut AnaptysBio from a “strong-buy” rating to a “hold” rating in a report on Saturday, May 16th. Wolfe Research reaffirmed an “outperform” rating and set a $78.00 target price on shares of AnaptysBio in a report on Monday, August 31st. TD Cowen decreased their price target on AnaptysBio from $75.00 to $70.00 and set a “buy” rating for the company in a research report on Tuesday, August 25th. Finally, UBS Group lifted their price target on AnaptysBio from $60.00 to $76.00 and gave the stock a “buy” rating in a research note on Wednesday, May 13th. Eleven analysts have rated the stock with a Buy rating, three have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, AnaptysBio presently has an average rating of “Moderate Buy” and a consensus price target of $79.85.

AnaptysBio Stock Down 1.1%

Shares of NASDAQ:ANAB opened at $56.80 on Friday. The company’s fifty day moving average is $58.18 and its two-hundred day moving average is $59.19. The company has a market cap of $1.68 billion, a P/E ratio of -52.59 and a beta of 0.71. AnaptysBio, Inc. has a 12-month low of $11.40 and a 12-month high of $72.36.

About AnaptysBio

AnaptysBio, Inc is a clinical-stage biotechnology company focused on the discovery and development of therapeutic antibody product candidates in immunology and inflammation. Founded in 2012 and headquartered in San Diego, California, AnaptysBio leverages a proprietary somatic hypermutation platform to rapidly generate and refine human antibodies with optimized efficacy and safety profiles. The company’s technology is designed to accelerate target validation and candidate selection across a range of immune-mediated conditions.

The company’s pipeline includes multiple clinical-stage programs addressing dermatological and inflammatory disorders.